SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment

Experimental and Clinical Endocrinology and Diabetes

Volumn 116, Issue 5, 2008, Pages 262-267

  Berthold, H K ^a   Laaksonen, R ^b   Lehtimaki T ^b   Gylling, H ^c   Krone, W ^d   Gouni Berthold, I ^d  

^a UNIVERSITY OF BONN   (Germany)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Campesterol; Cholesterol; Ezetimibe; Genetic variant; Lathosterol; SREBP; Statin

Indexed keywords

CAMPESTEROL; CHOLESTANOL; CHOLESTENOL; CHOLESTEROL; DESMOSTEROL; EZETIMIBE; GUANINE; LATHOSTEROL; SIMVASTATIN; SITOSTEROL;

ADULT; ALLELE; ARTICLE; CHOLESTEROL SYNTHESIS; DRUG POTENCY; DRUG RESPONSE; GENE; GENETIC POLYMORPHISM; GENOTYPE; GERMANY; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; LIPID ABSORPTION; LIPID METABOLISM; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SREBP 1C GENE;

ADULT; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; GENE FREQUENCY; GENOTYPE; HUMANS; HYPERCHOLESTEROLEMIA; INTESTINAL ABSORPTION; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 44849113536     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-993144     Document Type: Article

References (32)

1. Alrefai W, Annaba F, Sarwar Z et al. Modulation of human Niemann-Pick C1 like gene expression by sterol: role of sterol regulatory elements binding protein-2. Am J Physiol Gastrointest Liver Physiol epub ahead of print 2006
2. Davidson MH, MacGarry T, Bettis R, Melani L, Lipka LJ, Lebeaut AP, Suresh R, Sun S, Veltri EP. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2125-2134
3. Duan X, Zhu W, Li Y, Zhang Z, Zhao Y, Dao Y, Xiao Y. The effect of sterol regulatory element-binding protein 2 polymorphism on the serum lipid in northern Chinese subjects. J Lipid Res 2005; 46: 252-257
4. Ducluzeau PH, Perretti N, Laville M, Andreelli F, Vega N, Riou JP, Vidal H. Regulation by insulin of gene expression in human skeletal muscle and adipose tissue. Evidence for specific defects in type 2 diabetes. Diabetes 2001; 50: 1134-1142
5. During A, Dawson HD, Harrison EH. Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. J Nutr 2005; 135: 2305-2312
6. Eberle D, Clement K, Meyre D, Sahbatou M, Vaxillaire M, Gall A Le, Fene P, Basdevant A, Froguel P, Foufelle F. SREBF-1 gene polymorphisms are associated with obesity and type 2 diabetes in French obese diabetic cohorts. Diabetes 2004a; 53: 2153-2157
7. Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 2004b; 86: 839-848
8. Espenshade P, Li W, Yabe B. Sterols block binding of COPII proteins to SCAP, thereby controlling SCAP sorting in ER. Proc Natl Acad Sci USA 2002; 99: 11694-11699
9. Fiegenbaum M, Silveira FR, Sand CR Van der, Sand LC Van der, Ferreira ME, Pires RC, Hutz MH. Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes. Pharmacogenomics J 2005; 5: 359-364
10. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O'Neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA. The target of ezetimbe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005; 102: 8132-8137
11. Hegele RA, Guy J, Ban MR, Wang J. NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis 2005; 4: 16
12. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002; 4: 45-61
13. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-1131
14. Ketomaki A, Gylling H, Miettinen TA. Effects of plant stanol and sterol esters on serum phytosterols in a family with familial hypercholesterolemia including a homozygous sugject. J Lab Clin Med 2004; 143: 255-262
15. Knight BL, Patel DD, Humphreys SM, Wiggins D, Gibbons GF. Inhibition of cholesterol absorption associated with a PPARa-dependent increase in ABC binding cassette transporter A1 in mice. J Lipid Res 2003; 44: 2049-2058
16. Laaksonen R, Thelen KM, Päiva H, Matinheikki J, Vesalainen R, Janaruinen T, Knuuti J, Rontu R, Bergmann K von, Lütjohann D, Lehtimäki T. Genetic variant of the SREBF-1 gene is significantly related to cholesterol synthesis in man. Atherosclerosis 2006; 185: 206-209
17. Laudes M, Baroso I, Luan J, Soos MA, Yeo G, Meirhaeghe A, Logie L, Vidal-Puig A, Schafer AJ, Wareham NJ, O'Rahilly S. Genetic variants in human sterol regulatory element binding protein-1c in syndromes of severe insulin resistance and type 2 diabetes. Diabetes 2004; 53: 482-486
18. Miettinen TA, Tilvis RS, Kesaniemi YA. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 1990; 131: 20-31
19. Miserez A, Muller P, Barella L, Schwietert M, Erb P, Vernazza P, Battegay M. A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinemia. AIDS 2001; 15: 2045-2049
20. Miserez AR, Muller PY, Barella L, Barella S, Staehelin HB, Leitersdorf E, Kark JD, Friedlander Y. Sterol-regulatory element-binding protein (SREBP)-2 contributes to polygenic hypercholesterolemia. Atherosclerosis 2002; 164: 15-26
21. Muller PY, Miserez AR. Identification of mutations in the gene encoding sterol regulatory element binding protein (SREBP)-2 in hypercholesterlaemic subjects. J Med Genet 2002; 39: 271-275
22. Osborne TF. Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. J Biol Chem 2000; 275: 32379-32382
23. Rios DL, Vargas AF, Torres MR, Zago AJ, Callegari-Jacques SM, Hutz MH. Interaction between SREBP-1a and APOB polymorphisms influences total and low-density lipoprotein cholesterol levels in patients with coronary artery disease. Clin Genet 2003; 63: 380-385
24. Robinet P, Vedie B, Chironi G, Gariepy J, Simon A, Moatti N, Paul JL. Characterization of polymorphic structure of SREBP-2 gene: role in atherogenesis. Atherosclerosis 2003; 168: 381-387
25. Salek L, Lutucuta S, Ballantyne CM, Gotto Jr A, Marian AJ. Effects of SREBP-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. J Mol Med 2002; 80: 737-744
26. Sane AT, Sinnett D, Delvin E, Bendayan M, Mardi V, Menard D, Beaulieu J-F, Levy E. Localization and role of NPC1L1 in cholesterol absorption in human intestine. J Lipid Res 2006; 47: 2112-2120
27. Sewter C, Berger D, Considine RV, Medina G, Rochford J, Ciaraldi T, Henry R, Dohm L, Flier JS, O'Rahilly S, Vidal-Puig AJ. Human obesity and type 2 diabetes are associated with alterations in SREBP1 isoform expression that are reproduced ex vivo by tumor necrosis factor-alpha. Diabetes 2002; 51: 1035-1041
28. Shimomura I, Bashmakov Y, Shimano H, Horton JD, Goldstein JL, Brown MS. Cholesterol feeding reduces nuclear forms of sterol regulatory element binding proteins in hamster liver. Proc Natl Acad Sci USA 1997; 94: 12354-12359
29. Simon JS, Karnoub MC, Devlin DJ, Arreaza MG, Qiu P, Monks SA, Severino ME, Deutsch P, Palmisano J, Sachs AB, Bayne ML, Plump AS, Schadt EE. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics 2005; 86: 648-656
30. Vedie B, Jeunemaitre X, Megnien JL, Atger V, Simon A, Moatti N. A new DNA polymorphism in the 5′ untranslated region of the human SREBP-1a is related to development of atherosclersis in high cardiovascular risk population. Atherosclerosis 2001; 154: 589-597
31. Wang J, Williams CM, Hegele RA. Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe. Clin Genet 2005; 67: 175-177
32. Yang A, King MS, Han L, Isaacson JD, Mueller T, Grimm DR, Brun SC, Katz DA. Lack of correlation between SREBF1 genotype and hyperlipidemia in individuals treated with highly active antiretroviral therapy. AIDS 2003; 17: 2142-2143